Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)

NCT03249792 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

140

Enrollment

INDUSTRY

Sponsor class

Stopped Business Reasons

Conditions

Solid Tumor
Lymphoma

Interventions

DRUG: MK-2118 (IT)
DRUG: MK-2118 (SC)
BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC